Right Ventricular Dysfunction Staging System for Mortality Risk Stratifiction in Heart Failure with Preserved Ejection Fraction
Visualitza/
Impacte
Scholar |
Altres documents de l'autoria: Santas, Enrique; De la Espriella, Rafael; Chorro, Francisco J.; Palau, Patricia; Miñana, Gema; Heredia, Raquel; Amiguet Comins, Martina; Merenciano Gonzalez, Hector; Sanchis, Juan; Lupón, Josep; Bayes-Genis, Antoni; Núñez, Julio
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadades
Títol
Right Ventricular Dysfunction Staging System for Mortality Risk Stratifiction in Heart Failure with Preserved Ejection FractionAutoria
Data de publicació
2020-03-18Editor
MDPICita bibliogràfica
Santas E, De la Espriella R, Chorro FJ, et al. Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure With Preserved Ejection Fraction. J Clin Med. 2020;9(3):831. Published 2020 Mar 18. doi:10.3390/jcm9030831Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141269/Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging ... [+]
Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP ≥ 0.36 without significant TR; stage 2: TAPSE/PASP ≥ 0.36 with significant TR; stage 3: TAPSE/PASP < 0.36 without significant TR; and stage 4: TAPSE/PASP < 0.36 with significant TR. By the 1 year follow-up, 207 (23.4%) patients had died. We found a significant and graded association between RVD stages and mortality rates (15.8%, 25%, 31.2%, and 45.4% from stage 1 to stage 4, respectively; log-rank test, p < 0.001). After multivariable adjustment, and compared to stage 1, stages 3 and 4 were independently associated with mortality risk (HR: 1.8219; 95% CI 1.308-2.538; p < 0.001 and HR = 2.2632; 95% CI 1.540-3.325; p < 0.001, respectively). A RVD staging system, integrating TAPSE/PASP and TR, provides a comprehensive and widely available tool for risk stratification in HFpEF. [-]
Proyecto de investigación
the Ministry of Economy and Competitiveness, Instituto Carlos III (PI17/01426) ; CIBER Cardiovascular (16/11/00420 and 16/11/00403).Drets d'accés
info:eu-repo/semantics/openAccess
Apareix a les col.leccions
- MED_Articles [667]
Els següents fitxers sobre la llicència estan associats a aquest element:
Except where otherwise noted, this item's license is described as © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).